Champions Oncology, Inc.
CSBR Healthcare Biotechnology
Champions Oncology, Inc.’s revenue for fiscal 2026 (year ended April 2026) was $59.4 million, up 4.36% from fiscal 2025. In the quarter to July 2026, revenue grew 8.84%, EPS was flat and free cash flow fell 198.7%, each against the same quarter a year earlier.
Follow CSBR
Champions Oncology, Inc. (CSBR) Piotroski F-score
Champions Oncology, Inc.'s Piotroski F-score for fiscal 2026 is 3 out of 9: 3 of nine tests of profitability, leverage and efficiency passed, down from 8 in fiscal 2025.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2026 | 3 | (5.00) |
| FY2025 | 8 | 5.00 |
| FY2024 | 3 | 0.00 |
| FY2023 | 3 | (3.00) |
| FY2022 | 6 | 1.00 |
| FY2021 | 5 | 1.00 |
| FY2020 | 4 | (3.00) |
| FY2019 | 7 | 2.00 |
| FY2018 | 5 | 0.00 |
| FY2017 | 5 | — |
How fiscal 2026’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (3.96%) | 16.08% | Fail | 0 |
| Positive operating cash flow | (4.47m) | 7.39m | Fail | 0 |
| Rising return on assets | (3.96%) | 16.08% | Fail | 0 |
| Cash flow above net income | (3.30m) | 2.69m | Fail | 0 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 0.96 | 0.94 | Pass | 1 |
| No new shares issued | 13,832,000 | 13,660,000 | Fail | 0 |
| Rising gross margin | 48.00% | 50.15% | Fail | 0 |
| Rising asset turnover | 2.00 | 1.95 | Pass | 1 |
| Piotroski F-score | Weak — most fundamentals deteriorated | 3 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| VRCA Verrica Pharmaceuticals Inc. compare | 6 |
| HYFT MindWalk Holdings Corp. compare | 6 |
| SPRO Spero Therapeutics, Inc. compare | 5 |
| XBIT XBiotech Inc. compare | 3 |
| CSBR Champions Oncology, Inc. | 3 |
| NMAD Nomad Power Solutions, Inc. compare | — |
| MAIA MAIA Biotechnology, Inc. compare | — |
| CING Cingulate Inc. compare | — |
| OSTX OS Therapies Incorporated compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover